A Research Study Looking Into the Effect of NNC0519-0130 on Blood Levels of a Birth Control Pill and Emptying of the Stomach in Women After Menopause

• NNC0519-0130 (Drug): NNC0519-0130 will be administered subcutaneously.
• Levonorgestrel + Ethinylestradiol (Drug): Levonorgestrel + Ethinylestradiol will be administered orally.
• Paracetamol (Drug): Paracetamol will be administered orally.

Primary outcomes

• Area under the ethinylestradiol plasma concentration time curve during a dosing interval at steady state [Day 8]: Measured in hours picograms per milliliter (h*pg/mL).
• Area under the ethinylestradiol plasma concentration time curve during a dosing interval at steady state [Day 188]: Measured in h*pg/mL.
• Area under the levonorgestrel plasma concentration time curve during a dosing interval at steady state [Day 8]: Measured in h*pg/mL.
• Area under the levonorgestrel plasma concentration time curveduring a dosing interval at steady state [Day 188]: Measured in h*pg/mL.

Secondary outcomes

• Maximum ethinylestradiol plasma concentration at steady state [Day 8 and Day 188]: Measured in picograms per milliliter (pg/mL).
• Maximum levonorgestrel plasma concentration at steady state [Day 8 and Day 188]: Measured in pg/mL.
• Area under the paracetamol concentration-time curve for 0-300 minutes following a standardised meal [Day 1 and Day 181]: Measured in hours micrograms per milliliter (h*μg/mL).
• Area under the paracetamol concentration-time curve for 0-60 minutes following a standardised meal [Day 1 and Day 181]: Measured in h*μg/mL.
• Maximum paracetamol plasma concentration following a standardised meal [Day 1 and Day 181]: Measured in micrograms per milliliter (μg/mL).

Sex: Female, ages: any to 45 Years

Inclusion Criteria:

* Postmenopausal female.
* Age greater than or equal to (≥)45 years at the time of signing informed consent.
* Body weight ≥ 60 kilogram (kg).
* Body mass index (BMI) between 27.0 and 39.9 kilogram per square meter (kg/m\^2) (both inclusive) at screening. Overweight should be due to excess adipose tissue, as judged by the investigator.
* Considered to be otherwise healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator.

Exclusion Criteria:

* Any disorder, unwillingness or inability which in the investigator's opinion, might jeopardise the participant's safety or compliance with the protocol.
* Glycated haemoglobin (HbA1c) ≥ 6.5 percent (%) (48 millimoles per mole (mmol/mol)) at screening.
* Any contraindications for the use of the oral contraception used in the study according to the Microgynon Summary of Product Characteristics, including:

  1. Presence or risk of venous thromboembolism or arterial thromboembolism, e.g., history of migraine with focal neurological symptoms or transitory ischemic attacks.
  2. Undiagnosed vaginal bleeding.
  3. Presence or history of breast cancer.
  4. Presence or history of liver tumours (benign or malignant).
  5. Positive family history of arterial thromboembolism and/or venous thromboembolism (ever in a sibling or parent especially at relatively early age e.g. below 50).
  6. Known hereditary or acquired predisposition for arterial thromboembolism, such as hyperhomocysteinaemia and anti-phospholipid antibodies (anticardiolipinantibodies, lupus anticoagulant).
  7. Known hereditary or acquired predisposition to venous thromboembolism, such as Activated Protein C (APC) resistance (including factor V Leiden), antithrombin III deficiency, protein C deficiency or protein S deficiency.
  8. Dyslipoproteinaemia.
* Use of prescription medicinal products or non-prescription drugs including any herbal medicine known to interfere with the metabolic cytochrome P450 (CYP) pathways, such as hypericum (St. John's Wort), ginseng, garlic, milk thistle, and echinaceae, within 14 days before screening. Exceptions are routine vitamins, occasional use of paracetamol, ibuprofen and acetylsalicylic acid, or topical medication not reaching systemic circulation.
* Use of hormone replacement therapy within 4 weeks before screening or intention to initiate treatment with hormone replacement therapy during the study.
* Presence or history of any clinically relevant respiratory, metabolic, renal, hepatic, cardiovascular, gastrointestinal, or endocrinological conditions.

• Clinical Transparency (dept. 2834), Study director, Novo Nordisk A/S

NIH grants: 2023